For Patients with Metastatic Castration-Resistant Prostate Cancer, Abiraterone Delays Disease Progression
the Cancer Therapy Advisor take:
According to updated results published in the journal European Urology, researchers have found abiraterone significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy.
For the double-blind, placebo-controlled study, known as COU-AA-302, researchers enrolled 1,088 patients with mCRPC from April 2009 to June 2010. Patients were randomized to receive either abiraterone 1,000 mg plus prednisone 5 mg twice daily orally or prednisone alone.
The researchers followed patients for a median of 27.1 months and found a significantly improvement in progression-free survival in patients treated with abiraterone plus prednisone versus prednisone alone (median: 16.5 vs 8.2 months; HR = 0.52, 95% CI: 0.45-0.61, P < 0.0001).
Abiraterone was found to improve overall survival (35.3 versus 30.1 months), but the finding was not statistically significant. Results also showed that treatment with abiraterone delayed pain and functional deterioration. A favorable safety profile was also observed, even in patients treated with abiraterone for more than 2 years. This study is still ongoing.
Abiraterone significantly improves progression-free survival in mCRPC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials
- Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma